Axsome Therapeutics (AXSM) Financials

$112.16 -4.33 (-3.72%)

Closing price 04:00 PM Eastern

Extended Trading

$110.72 -1.44 (-1.29%)

As of 06:31 PM Eastern

Annual Income Statements for Axsome Therapeutics

This table shows Axsome Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-12	-27	-29	-31	-68	-103	-130	-187	-239	-287
Consolidated Net Income / (Loss)	-12	-27	-29	-31	-68	-103	-130	-187	-239	-287
Net Income / (Loss) Continuing Operations	-12	-27	-29	-31	-68	-103	-130	-187	-239	-287
Total Pre-Tax Income	-12	-28	-29	-31	-68	-103	-130	-187	-238	-287
Total Operating Income	-9.20	-28	-27	-33	-67	-99	-125	-180	-232	-281
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	45	245	352
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	50	271	386
Operating Revenue	-	-	-	-	-	0.00	0.00	50	271	386
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.20	26	33
Operating Cost of Revenue	-	-	-	-	-	0.00	0.00	5.20	26	33
Total Operating Expenses	9.20	28	27	33	67	99	125	225	476	633
Selling, General & Admin Expense	2.42	6.34	7.21	9.35	14	29	67	159	323	411
Research & Development Expense	6.78	21	20	23	54	70	58	58	98	187
Amortization Expense	-	-	-	-	-	0.00	0.00	4.14	6.38	6.39
Other Operating Expenses / (Income)	-	-	-	-	-	0.00	0.00	3.30	49	28
Total Other Income / (Expense), net	-3.29	-0.13	-1.99	1.66	-1.24	-3.81	-5.70	-7.34	-6.45	-6.57
Interest & Investment Income	-0.74	-0.13	-1.34	-1.13	-1.24	-2.57	-5.70	-7.34	-6.45	-6.57
Income Tax Expense	-	-	-	-0.22	-	-0.05	0.00	0.00	0.96	0.09
Other Gains / (Losses), net	0.00	0.47	0.21	-	0.14	-	0.00	0.00	0.00	0.00
Basic Earnings per Share	($1.02)	($1.42)	($1.27)	($1.15)	($2.01)	($2.77)	($3.47)	($4.60)	($5.27)	($5.99)
Weighted Average Basic Shares Outstanding	11.95M	19.15M	22.76M	26.88M	34.02M	37.21M	37.62M	40.66M	45.43M	47.91M
Diluted Earnings per Share	($1.02)	($1.42)	($1.27)	($1.15)	($2.01)	($2.77)	($3.47)	($4.60)	($5.27)	($5.99)
Weighted Average Diluted Shares Outstanding	11.95M	19.15M	22.76M	26.88M	34.02M	37.21M	37.62M	40.66M	45.43M	47.91M
Weighted Average Basic & Diluted Shares Outstanding	11.95M	19.15M	22.76M	26.88M	34.02M	37.21M	37.62M	43.52M	47.37M	48.77M

This table shows Axsome Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-45	-61	-11	-67	-62	-99	-68	-79	-65	-75
Consolidated Net Income / (Loss)	-45	-61	-11	-67	-62	-99	-68	-79	-65	-75
Net Income / (Loss) Continuing Operations	-45	-61	-11	-67	-62	-99	-68	-79	-65	-75
Total Pre-Tax Income	-45	-61	-8.64	-68	-63	-99	-68	-79	-65	-75
Total Operating Income	-42	-60	-6.37	-65	-62	-98	-67	-78	-63	-73
Total Gross Profit	15	22	87	42	51	64	69	79	96	108
Total Revenue	17	24	95	47	58	72	75	87	105	119
Operating Revenue	17	24	95	47	58	72	75	87	105	119
Total Cost of Revenue	1.92	2.29	7.56	4.60	6.53	7.38	6.30	8.06	8.44	11
Operating Cost of Revenue	1.92	2.29	7.56	4.60	6.53	7.38	6.30	8.06	8.44	11
Total Operating Expenses	57	82	93	107	113	162	136	157	159	181
Selling, General & Admin Expense	41	61	74	79	83	87	99	104	96	113
Research & Development Expense	15	15	18	21	29	31	37	50	45	55
Amortization Expense	1.61	1.61	1.57	1.59	1.61	1.61	1.59	1.59	1.61	1.61
Other Operating Expenses / (Income)	-0.04	4.20	-0.16	6.05	-0.18	43	-1.41	2.16	16	11
Total Other Income / (Expense), net	-2.41	-1.32	-2.26	-2.73	-0.76	-0.70	-1.08	-1.30	-1.98	-2.21
Interest & Investment Income	-2.41	-1.32	-2.26	-2.73	-0.76	-0.70	-1.08	-1.30	-1.98	-2.21
Income Tax Expense	0.00	-	2.58	-0.62	-0.68	-0.33	0.00	0.00	0.00	0.09
Basic Earnings per Share	($1.07)	($1.44)	($0.26)	($1.54)	($1.32)	($2.15)	($1.44)	($1.67)	($1.34)	($1.54)
Weighted Average Basic Shares Outstanding	41.70M	40.66M	43.52M	43.67M	47.12M	45.43M	47.39M	47.57M	48.14M	47.91M
Diluted Earnings per Share	($1.07)	($1.44)	($0.26)	($1.54)	($1.32)	($2.15)	($1.44)	($1.67)	($1.34)	($1.54)
Weighted Average Diluted Shares Outstanding	41.70M	40.66M	43.52M	43.67M	47.12M	45.43M	47.39M	47.57M	48.14M	47.91M
Weighted Average Basic & Diluted Shares Outstanding	43.43M	43.52M	43.57M	47.19M	47.32M	47.37M	47.50M	48.00M	48.46M	48.77M

This table details how cash moves in and out of Axsome Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	45	-11	-2.60	-20	206	-36	-97	114	185	-71
Net Cash From Operating Activities	-7.44	-21	-26	-30	-46	-78	-108	-117	-145	-128
Net Cash From Continuing Operating Activities	-7.44	-21	-26	-30	-46	-78	-108	-117	-145	-128
Net Income / (Loss) Continuing Operations	-12	-27	-29	-31	-68	-103	-130	-187	-239	-287
Consolidated Net Income / (Loss)	-12	-27	-29	-31	-68	-103	-130	-187	-239	-287
Depreciation Expense	0.00	0.02	0.04	0.05	0.04	0.02	0.08	0.26	0.46	0.53
Amortization Expense	0.05	0.07	0.47	0.38	0.65	0.84	1.08	5.62	8.95	10
Non-Cash Adjustments To Reconcile Net Income	3.78	2.03	2.72	-1.04	6.12	23	21	41	113	114
Changes in Operating Assets and Liabilities, net	0.94	3.80	-0.81	1.52	15	0.41	0.32	24	-28	34
Net Cash From Investing Activities	-0.02	-0.10	-0.01	-0.03	-0.02	-0.05	-0.31	-54	-0.58	-0.27
Net Cash From Continuing Investing Activities	-0.02	-0.10	-0.01	-0.03	-0.02	-0.05	-0.31	-54	-0.58	-0.27
Purchase of Property, Plant & Equipment	-0.02	-0.10	-0.01	-0.03	-0.02	-0.05	-0.31	-0.70	-0.58	-0.27
Acquisitions	-	-	-	-	-	0.00	0.00	-53	0.00	0.00
Net Cash From Financing Activities	53	9.97	24	10	252	42	11	285	331	58
Net Cash From Continuing Financing Activities	53	9.97	24	10	252	42	11	285	331	58
Repayment of Debt	0.00	-0.06	-0.28	-3.36	-7.24	-23	-0.31	-0.49	-1.44	0.00
Repurchase of Common Equity	-	-	-	-	0.00	-	-0.22	-6.98	-16	-0.82
Issuance of Debt	7.44	10	0.00	0.00	20	50	0.00	45	85	0.00
Issuance of Common Equity	46	0.00	24	13	238	14	7.44	250	259	71
Other Financing Activities, net	0.00	0.03	0.48	0.51	1.39	1.05	4.23	-2.97	4.37	-13
Cash Interest Paid	-	0.05	0.87	0.77	1.29	2.10	4.63	7.69	17	20

This table details how cash moves in and out of Axsome Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	154	-27	46	191	-21	-30	-55	-16	12	-12
Net Cash From Operating Activities	-23	-28	-5.82	-55	-54	-30	-53	-30	-19	-26
Net Cash From Continuing Operating Activities	-23	-28	-5.82	-55	-54	-30	-53	-30	-19	-26
Net Income / (Loss) Continuing Operations	-45	-61	-11	-67	-62	-99	-68	-79	-65	-75
Consolidated Net Income / (Loss)	-45	-61	-11	-67	-62	-99	-68	-79	-65	-75
Depreciation Expense	0.07	0.09	0.09	0.10	0.14	0.13	0.13	0.14	0.13	0.13
Amortization Expense	2.06	1.95	2.16	2.50	2.23	2.06	2.32	2.49	2.60	2.65
Non-Cash Adjustments To Reconcile Net Income	8.67	15	13	23	15	63	19	24	38	33
Changes in Operating Assets and Liabilities, net	11	17	-9.63	-14	-8.66	3.43	-6.81	23	5.08	13
Net Cash From Investing Activities	-0.07	-0.18	-0.07	-0.13	-0.37	-0.01	-0.10	-0.05	-0.09	-0.03
Net Cash From Continuing Investing Activities	-0.07	-0.18	-0.07	-0.13	-0.37	-0.01	-0.10	-0.05	-0.09	-0.03
Purchase of Property, Plant & Equipment	-0.07	-0.18	-0.07	-0.13	-0.37	-0.01	-0.10	-0.05	-0.09	-0.03
Net Cash From Financing Activities	177	1.07	52	246	33	-0.00	-1.19	14	30	14
Net Cash From Continuing Financing Activities	177	1.07	52	246	33	-0.00	-1.19	14	30	14
Repurchase of Common Equity	-5.22	-	-	-	-2.05	-	-	-	-0.26	-0.33
Issuance of Common Equity	180	6.25	-	-	45	-11	-	-	43	18
Other Financing Activities, net	1.97	-5.19	-2.22	4.93	-8.75	10	-1.19	3.34	-12	-2.99
Cash Interest Paid	2.53	2.57	3.22	3.92	4.73	4.87	4.90	5.01	5.02	4.76

This table presents Axsome Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	49	38	36	15	221	186	88	331	588	568
Total Current Assets	49	38	35	15	220	184	87	246	504	485
Cash & Equivalents	48	37	34	14	220	184	86	201	386	315
Accounts Receivable	-	-	-	-	-	-	0.00	38	95	142
Inventories, net	-	-	-	-	-	-	0.00	4.32	15	16
Prepaid Expenses	1.00	1.38	1.28	1.25	0.41	0.15	0.05	2.78	8.12	12
Plant, Property, & Equipment, net	0.02	0.10	0.07	0.05	0.03	0.05	0.28	0.72	0.85	0.58
Total Noncurrent Assets	0.03	0.11	0.19	0.11	0.14	2.06	0.98	85	83	83
Goodwill	-	-	-	-	-	-	0.00	10	12	12
Intangible Assets	-	-	-	-	-	-	0.00	60	53	47
Other Noncurrent Operating Assets	0.03	0.11	0.19	0.11	0.14	2.06	0.98	15	18	24
Total Liabilities & Shareholders' Equity	49	38	36	15	221	186	88	331	588	568
Total Liabilities	2.63	17	19	14	42	72	72	222	397	511
Total Current Liabilities	2.63	7.17	12	11	24	23	23	97	139	230
Short-Term Debt	0.00	0.27	3.27	3.29	2.60	-	0.00	5.90	6.41	8.29
Accounts Payable	2.63	6.90	6.11	7.53	22	22	22	90	131	220
Other Current Liabilities	-	0.00	2.79	-	0.00	1.22	0.62	0.43	1.27	1.84
Total Noncurrent Liabilities	0.00	9.47	6.66	3.62	17	49	49	125	258	281
Long-Term Debt	0.00	9.47	6.66	3.62	17	48	49	94	178	181
Capital Lease Obligations	-	-	-	-	-	-	-	-	0.00	2.94
Other Noncurrent Operating Liabilities	-	-	-	-	0.00	0.58	0.00	31	80	98
Total Equity & Noncontrolling Interests	46	22	17	0.94	179	114	16	110	191	57
Total Preferred & Common Equity	46	22	17	0.94	179	114	16	110	191	57
Preferred Stock	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	46	22	17	0.94	179	114	16	110	191	57
Common Stock	67	69	93	108	355	393	425	706	1,027	1,180
Retained Earnings	-20	-48	-77	-108	-176	-279	-409	-596	-836	-1,123

This table presents Axsome Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	339	389	612	601	546	548	561
Total Current Assets	252	304	520	512	460	463	479
Cash & Equivalents	228	247	437	417	331	316	327
Accounts Receivable	20	45	67	78	101	120	124
Inventories, net	2.10	7.94	9.25	9.99	16	15	14
Prepaid Expenses	2.46	5.20	5.91	6.80	12	12	13
Plant, Property, & Equipment, net	0.63	0.70	0.74	0.97	0.81	0.72	0.68
Total Noncurrent Assets	86	84	91	88	84	84	82
Goodwill	12	10	12	12	12	12	12
Intangible Assets	61	58	57	55	52	50	49
Other Noncurrent Operating Assets	13	16	23	21	21	22	21
Total Liabilities & Shareholders' Equity	339	389	612	601	546	548	561
Total Liabilities	182	277	333	331	402	445	469
Total Current Liabilities	60	101	115	115	144	187	196
Short-Term Debt	7.00	6.00	6.34	6.67	6.39	7.04	8.13
Accounts Payable	53	95	108	108	137	178	186
Other Current Liabilities	0.42	0.11	0.35	0.44	1.15	1.42	1.63
Total Noncurrent Liabilities	121	177	218	217	258	259	272
Long-Term Debt	94	148	177	177	179	179	180
Capital Lease Obligations	-	-	-	-	1.70	3.03	2.95
Other Noncurrent Operating Liabilities	27	29	41	39	77	76	89
Total Equity & Noncontrolling Interests	157	112	279	270	144	103	93
Total Preferred & Common Equity	157	112	279	270	144	103	93
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	157	112	279	270	144	103	93
Common Stock	692	719	954	1,006	1,048	1,086	1,141
Retained Earnings	-535	-608	-675	-737	-904	-983	-1,048

This table displays calculated financial ratios and metrics derived from Axsome Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	440.80%	42.53%
EBITDA Growth	-12.35%	-196.76%	0.57%	-8.55%	-124.62%	-47.66%	-25.72%	-40.76%	-27.89%	-21.38%
EBIT Growth	-62.41%	-196.01%	-0.97%	-8.07%	-123.74%	-47.43%	-25.79%	-44.18%	-28.94%	-21.02%
NOPAT Growth	-62.13%	-199.51%	1.38%	-20.92%	-104.72%	-47.43%	-25.79%	-44.18%	-28.94%	-21.02%
Net Income Growth	-103.49%	-122.77%	-6.40%	-6.99%	-120.71%	-50.56%	-26.73%	-43.50%	-27.84%	-20.05%
EPS Growth	-54.55%	-39.22%	10.56%	9.45%	-74.78%	-37.81%	-25.27%	-32.56%	-14.57%	-13.66%
Operating Cash Flow Growth	-61.84%	-186.08%	-24.39%	-13.53%	-54.31%	-69.18%	-37.94%	-7.66%	-24.52%	11.49%
Free Cash Flow Firm Growth	0.00%	-221.23%	-8.90%	-43.03%	-31.51%	-116.25%	-26.63%	-79.24%	8.83%	1.36%
Invested Capital Growth	0.00%	-233.38%	-38.89%	16.98%	-248.18%	-2.13%	0.04%	140.79%	-221.03%	-518.31%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	94.95%	21.11%	13.96%
EBITDA Q/Q Growth	0.00%	-18.57%	0.00%	0.00%	-28.81%	15.47%	-26.71%	-17.24%	-20.74%	8.86%
EBIT Q/Q Growth	0.00%	-18.89%	0.00%	0.00%	-28.66%	15.23%	-26.33%	-17.91%	-19.83%	8.38%
NOPAT Q/Q Growth	0.00%	-19.38%	0.00%	0.00%	-28.66%	15.23%	-26.33%	-17.91%	-19.83%	8.38%
Net Income Q/Q Growth	0.00%	-17.06%	0.00%	0.00%	-28.63%	14.01%	-24.83%	-17.05%	-18.54%	7.63%
EPS Q/Q Growth	0.00%	-10.94%	0.00%	0.00%	-24.07%	-2.59%	-3.27%	-13.30%	-15.57%	9.24%
Operating Cash Flow Q/Q Growth	0.00%	-30.44%	3.38%	-13.19%	-20.14%	-3.96%	-8.29%	1.08%	-1.97%	3.14%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	13.66%	-33.41%	2.34%	-0.66%	-5.08%
Invested Capital Q/Q Growth	0.00%	6.97%	0.00%	0.00%	-24.89%	-14.10%	4.30%	-71.15%	-128.98%	-53.14%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	89.61%	90.37%	91.37%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-347.57%	-82.19%	-69.99%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-359.33%	-85.67%	-72.74%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-359.33%	-85.67%	-72.74%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-373.99%	-88.41%	-74.47%
Tax Burden Percent	97.80%	98.29%	99.29%	99.30%	99.80%	99.95%	100.00%	100.00%	100.40%	100.03%
Interest Burden Percent	134.18%	100.48%	104.82%	103.75%	101.84%	103.85%	104.57%	104.08%	102.78%	102.34%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-26.29%	-79.99%	-151.19%	-350.78%	-76.08%	-70.36%	-201.51%	-298.97%	-159.21%	-231.63%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,763.61%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-85.77%	-50.41%	-48.51%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-89.27%	-52.02%	-49.66%
Return on Common Equity (ROCE)	-26.29%	-79.99%	-151.19%	-350.78%	-76.08%	-70.36%	-201.51%	-298.97%	-159.21%	-231.63%
Return on Equity Simple (ROE_SIMPLE)	-26.29%	-126.10%	-173.14%	-3,301.50%	-38.24%	-90.43%	-834.29%	-170.81%	-125.27%	-503.76%
Net Operating Profit after Tax (NOPAT)	-6.44	-19	-19	-23	-47	-69	-87	-126	-162	-196
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-251.53%	-59.97%	-50.92%
Net Nonoperating Expense Percent (NNEP)	-24.04%	-21.15%	-38.96%	-51.20%	-20.55%	-19.97%	-49.85%	-88.76%	-50.90%	-55.87%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-60.01%	-43.22%	-78.89%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	10.39%	9.63%	8.63%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	318.27%	119.41%	106.65%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	115.81%	36.20%	48.50%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	448.94%	176.04%	164.11%
Earnings before Interest and Taxes (EBIT)	-9.30	-28	-28	-30	-67	-99	-125	-180	-232	-281
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-9.25	-27	-27	-30	-67	-98	-124	-174	-222	-270
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	5.99	7.93	89.64	19.96	26.74	91.10	30.57	19.72	71.92
Price to Tangible Book Value (P/TBV)	0.00	5.99	7.93	89.64	19.96	26.74	91.10	84.61	29.97	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	66.94	13.92	10.63
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	366.14	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	64.93	13.17	10.31
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.45	0.59	7.37	0.11	0.42	3.14	0.91	0.97	3.37
Long-Term Debt to Equity	0.00	0.44	0.40	3.86	0.10	0.42	3.14	0.86	0.93	3.22
Financial Leverage	-1.03	-1.10	-1.33	-1.76	-1.15	-1.15	-1.34	-1.10	-1.01	-1.31
Leverage Ratio	1.06	1.28	1.93	2.89	1.31	1.39	2.12	3.35	3.06	4.66
Compound Leverage Factor	1.42	1.29	2.02	2.99	1.34	1.44	2.21	3.49	3.15	4.77
Debt to Total Capital	0.00%	31.11%	37.27%	88.05%	10.03%	29.81%	75.85%	47.76%	49.13%	77.10%
Short-Term Debt to Total Capital	0.00%	0.86%	12.27%	41.94%	1.31%	0.00%	0.00%	2.81%	1.71%	3.33%
Long-Term Debt to Total Capital	0.00%	30.25%	25.00%	46.11%	8.72%	29.81%	75.85%	44.95%	47.43%	73.77%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	68.89%	62.73%	11.95%	89.97%	70.19%	24.15%	52.24%	50.87%	22.90%
Debt to EBITDA	0.00	-0.35	-0.36	-0.23	-0.30	-0.49	-0.40	-0.58	-0.83	-0.71
Net Debt to EBITDA	0.00	0.98	0.88	0.24	3.01	1.38	0.30	0.58	0.91	0.46
Long-Term Debt to EBITDA	0.00	-0.35	-0.24	-0.12	-0.26	-0.49	-0.40	-0.54	-0.80	-0.68
Debt to NOPAT	0.00	-0.51	-0.52	-0.30	-0.42	-0.70	-0.56	-0.80	-1.14	-0.98
Net Debt to NOPAT	0.00	1.39	1.27	0.31	4.25	1.95	0.43	0.80	1.24	0.63
Long-Term Debt to NOPAT	0.00	-0.49	-0.35	-0.16	-0.37	-0.70	-0.56	-0.75	-1.10	-0.94
Altman Z-Score	0.00	1.51	-0.59	-12.40	50.11	22.41	1.49	5.44	3.60	1.63
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	18.63	5.30	2.90	1.41	9.00	7.85	3.75	2.54	3.63	2.11
Quick Ratio	18.25	5.11	2.79	1.29	8.98	7.85	3.75	2.47	3.46	1.99
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-4.85	-16	-17	-24	-32	-69	-87	-156	-143	-141
Operating Cash Flow to CapEx	-36,835.81%	-20,353.00%	-267,444.45%	-91,918.59%	-287,668.62%	-170,962.87%	-35,138.31%	-16,597.01%	-24,927.84%	-47,559.26%
Free Cash Flow to Firm to Interest Expense	-1.98	0.00	0.00	0.00	0.00	-55.29	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-3.04	0.00	0.00	0.00	0.00	-62.92	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-3.05	0.00	0.00	0.00	0.00	-62.95	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.24	0.59	0.67
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.08	3.26
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.68	2.16
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	99.49	345.15	539.43
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.09	0.24	0.19
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	89.37	112.06
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	136.22	169.15
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3,956.17	1,550.29	1,924.37
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3,956.17	-1,324.70	-1,643.17
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-1.59	-5.31	-7.37	-6.12	-21	-22	-22	8.87	-11	-66
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-7.77	-290.03	-10.00
Increase / (Decrease) in Invested Capital	-1.59	-3.72	-2.06	1.25	-15	-0.45	0.01	31	-20	-56
Enterprise Value (EV)	0.00	102	108	77	3,367	2,907	1,387	3,249	3,564	3,977
Market Capitalization	0.00	129	133	84	3,567	3,042	1,424	3,349	3,766	4,100
Book Value per Share	$3.89	$1.13	$0.71	$0.03	$5.18	$3.06	$0.41	$2.52	$4.04	$1.18
Tangible Book Value per Share	$3.89	$1.13	$0.71	$0.03	$5.18	$3.06	$0.41	$0.91	$2.66	($0.04)
Total Capital	46	31	27	7.85	199	162	65	210	375	249
Total Debt	0.00	9.74	9.93	6.91	20	48	49	100	184	192
Total Long-Term Debt	0.00	9.47	6.66	3.62	17	48	49	94	178	184
Net Debt	-48	-27	-24	-7.06	-200	-136	-37	-101	-202	-123
Capital Expenditures (CapEx)	0.02	0.10	0.01	0.03	0.02	0.05	0.31	0.70	0.58	0.27
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.64	-5.52	-7.63	-6.28	-21	-23	-23	-46	-14	-52
Debt-free Net Working Capital (DFNWC)	46	31	26	7.68	198	161	63	155	372	263
Net Working Capital (NWC)	46	31	23	4.39	196	161	63	149	365	255
Net Nonoperating Expense (NNE)	5.77	7.92	9.93	7.97	21	34	43	61	77	91
Net Nonoperating Obligations (NNO)	-48	-27	-24	-7.06	-200	-136	-37	-101	-202	-123
Total Depreciation and Amortization (D&A)	0.05	0.09	0.51	0.42	0.69	0.86	1.15	5.89	9.41	11
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-91.65%	-5.31%	-13.51%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	309.73%	137.40%	68.25%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	297.94%	135.04%	66.10%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.02)	($1.42)	($1.27)	($1.15)	($2.01)	($2.77)	($3.47)	($4.60)	($5.27)	($5.99)
Adjusted Weighted Average Basic Shares Outstanding	11.95M	19.20M	25.49M	33.28M	37.08M	37.41M	38.48M	40.66M	45.43M	47.91M
Adjusted Diluted Earnings per Share	($1.02)	($1.42)	($1.27)	($1.15)	($2.01)	($2.77)	($3.47)	($4.60)	($5.27)	($5.99)
Adjusted Weighted Average Diluted Shares Outstanding	11.95M	19.20M	25.49M	33.28M	37.08M	37.41M	38.48M	40.66M	45.43M	47.91M
Adjusted Basic & Diluted Earnings per Share	($1.02)	($1.42)	($1.27)	($1.15)	($2.01)	($2.77)	($3.47)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	11.95M	19.15M	22.76M	26.88M	34.02M	37.21M	37.62M	43.52M	47.37M	48.77M
Normalized Net Operating Profit after Tax (NOPAT)	-6.44	-19	-19	-23	-47	-69	-87	-126	-162	-196
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-251.53%	-59.97%	-50.92%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-373.99%	-88.06%	-74.45%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-3.81	0.00	0.00	0.00	0.00	-79.50	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-2.63	0.00	0.00	0.00	0.00	-55.65	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-3.81	0.00	0.00	0.00	0.00	-79.54	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-2.64	0.00	0.00	0.00	0.00	-55.69	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.17%	-3.73%	-6.55%	-0.28%

This table displays calculated financial ratios and metrics derived from Axsome Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	429.48%	243.07%	193.50%	-20.70%	86.65%	81.27%	66.04%
EBITDA Growth	-19.63%	-79.17%	89.07%	-64.35%	-48.34%	-66.00%	-1,470.37%	-20.74%	-0.24%	27.31%
EBIT Growth	-26.95%	-83.75%	83.35%	-66.04%	-46.47%	-64.02%	-955.46%	-19.97%	-0.81%	26.11%
NOPAT Growth	-26.95%	-83.75%	83.35%	-66.04%	-46.47%	-64.02%	-955.46%	-19.97%	-0.81%	26.11%
Net Income Growth	-28.50%	-80.25%	71.69%	-62.10%	-38.77%	-61.09%	-509.35%	-18.13%	-3.86%	24.06%
EPS Growth	-15.05%	-60.00%	74.76%	-45.28%	-23.36%	-49.31%	-453.85%	-8.44%	-1.52%	28.37%
Operating Cash Flow Growth	15.01%	4.43%	82.17%	-65.04%	-135.29%	-10.15%	-818.52%	45.60%	65.21%	13.70%
Free Cash Flow Firm Growth	-321.64%	-217.80%	-70.33%	67.41%	40.14%	32.23%	37.49%	78.17%	173.47%	109.82%
Invested Capital Growth	235.29%	140.79%	191.38%	-39.70%	20.51%	-221.03%	-103.34%	-194.19%	-216.99%	-518.31%
Revenue Q/Q Growth	91.00%	44.67%	288.07%	-50.62%	23.76%	23.77%	4.85%	16.22%	20.19%	13.37%
EBITDA Q/Q Growth	-5.99%	-43.70%	92.87%	-1,413.06%	4.34%	-60.80%	32.53%	-16.33%	20.58%	-16.61%
EBIT Q/Q Growth	-8.25%	-41.27%	89.36%	-920.66%	4.51%	-58.20%	31.54%	-16.01%	19.76%	-15.96%
NOPAT Q/Q Growth	-8.25%	-41.27%	89.36%	-920.66%	4.51%	-58.20%	31.54%	-16.01%	19.76%	-15.96%
Net Income Q/Q Growth	-8.17%	-36.63%	81.68%	-498.77%	7.40%	-58.61%	30.71%	-16.07%	18.58%	-15.96%
EPS Q/Q Growth	-0.94%	-34.58%	81.94%	-492.31%	14.29%	-62.88%	33.02%	-15.97%	19.76%	-14.93%
Operating Cash Flow Q/Q Growth	32.14%	-21.11%	78.88%	-850.85%	3.25%	43.30%	-76.10%	43.68%	38.12%	-40.64%
Free Cash Flow Firm Q/Q Growth	7.11%	12.75%	39.27%	33.79%	-70.64%	1.23%	43.98%	76.88%	674.39%	-86.80%
Invested Capital Q/Q Growth	-25.38%	-71.15%	113.14%	31.41%	49.12%	-128.98%	94.12%	-3,609.98%	-85.22%	-53.14%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	88.58%	90.60%	92.01%	90.15%	88.70%	89.69%	91.60%	90.76%	91.95%	91.15%
EBITDA Margin	-239.10%	-237.49%	-4.36%	-133.75%	-103.38%	-134.32%	-86.43%	-86.52%	-57.17%	-58.80%
Operating Margin	-251.76%	-245.85%	-6.74%	-139.31%	-107.49%	-137.39%	-89.70%	-89.54%	-59.78%	-61.14%
EBIT Margin	-251.76%	-245.85%	-6.74%	-139.31%	-107.49%	-137.39%	-89.70%	-89.54%	-59.78%	-61.14%
Profit (Net Income) Margin	-266.08%	-251.29%	-11.86%	-143.83%	-107.62%	-137.92%	-91.14%	-91.03%	-61.67%	-63.08%
Tax Burden Percent	100.00%	100.00%	129.87%	99.09%	98.92%	99.67%	100.00%	100.00%	100.00%	100.11%
Interest Burden Percent	105.68%	102.21%	135.52%	104.20%	101.22%	100.71%	101.61%	101.66%	103.16%	103.04%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-1,127.57%	0.00%	0.00%	-538.73%	-495.80%	0.00%	-1,724.41%	-25,321.38%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-1,111.81%	0.00%	0.00%	-519.75%	-485.37%	0.00%	-1,706.51%	-25,308.38%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	1,067.23%	0.00%	0.00%	402.95%	408.26%	0.00%	1,584.57%	25,212.69%	0.00%	0.00%
Return on Equity (ROE)	-60.34%	-298.97%	-250.92%	-135.77%	-87.54%	-159.21%	-139.84%	-108.69%	-171.61%	-231.63%
Cash Return on Invested Capital (CROIC)	-521.00%	-1,763.61%	-756.81%	-318.68%	-418.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-28.37%	-58.68%	-4.08%	-64.18%	-51.11%	-80.85%	-48.17%	-45.00%	-34.81%	-40.77%
Return on Assets (ROA)	-29.98%	-59.98%	-7.18%	-66.27%	-51.17%	-81.16%	-48.94%	-45.75%	-35.91%	-42.06%
Return on Common Equity (ROCE)	-60.34%	-298.97%	-250.92%	-135.77%	-87.54%	-159.21%	-139.84%	-108.69%	-171.61%	-231.63%
Return on Equity Simple (ROE_SIMPLE)	-101.59%	0.00%	-141.95%	-66.16%	-74.89%	0.00%	-205.77%	-300.00%	-334.73%	0.00%
Net Operating Profit after Tax (NOPAT)	-30	-42	-4.46	-46	-43	-69	-47	-55	-44	-51
NOPAT Margin	-176.23%	-172.10%	-4.72%	-97.52%	-75.24%	-96.17%	-62.79%	-62.68%	-41.84%	-42.80%
Net Nonoperating Expense Percent (NNEP)	-15.76%	-27.96%	-10.53%	-18.98%	-10.42%	-19.75%	-17.90%	-13.00%	-11.26%	-14.81%
Return On Investment Capital (ROIC_SIMPLE)	-	-20.00%	-	-	-	-18.32%	-	-	-	-20.42%
Cost of Revenue to Revenue	11.42%	9.40%	7.99%	9.85%	11.30%	10.31%	8.40%	9.24%	8.05%	8.85%
SG&A Expenses to Revenue	242.74%	252.34%	78.45%	169.03%	143.94%	121.36%	131.96%	118.80%	91.22%	95.37%
R&D to Revenue	88.31%	60.29%	18.81%	44.07%	49.78%	43.06%	49.11%	57.19%	43.32%	46.31%
Operating Expenses to Revenue	340.34%	336.45%	98.75%	229.46%	196.18%	227.07%	181.31%	180.30%	151.72%	152.29%
Earnings before Interest and Taxes (EBIT)	-42	-60	-6.37	-65	-62	-98	-67	-78	-63	-73
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-40	-58	-4.13	-62	-60	-96	-65	-75	-60	-70
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	11.43	30.57	24.01	11.23	12.24	19.72	26.22	37.17	46.44	71.92
Price to Tangible Book Value (P/TBV)	21.36	84.61	61.83	14.89	16.28	29.97	47.03	93.93	133.33	0.00
Price to Revenue (P/Rev)	70.07	66.94	18.56	17.16	14.76	13.92	15.04	13.12	12.75	10.63
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	54.36	366.14	137.01	115.77	82.72	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	65.14	64.93	17.92	15.77	13.72	13.17	14.47	12.68	12.34	10.31
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.64	0.91	1.37	0.66	0.68	0.97	1.30	1.84	2.06	3.37
Long-Term Debt to Equity	0.60	0.86	1.32	0.63	0.66	0.93	1.25	1.77	1.97	3.22
Financial Leverage	-0.96	-1.10	-1.01	-0.78	-0.84	-1.01	-0.93	-1.00	-1.02	-1.31
Leverage Ratio	2.28	3.35	3.78	2.69	2.20	3.06	3.65	3.04	3.21	4.66
Compound Leverage Factor	2.41	3.42	5.12	2.81	2.23	3.08	3.71	3.09	3.31	4.81
Debt to Total Capital	39.07%	47.76%	57.87%	39.65%	40.59%	49.13%	56.46%	64.81%	67.29%	77.10%
Short-Term Debt to Total Capital	2.71%	2.81%	2.26%	1.37%	1.47%	1.71%	1.93%	2.41%	2.86%	3.33%
Long-Term Debt to Total Capital	36.36%	44.95%	55.61%	38.28%	39.12%	47.43%	54.53%	62.40%	64.42%	73.77%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	60.93%	52.24%	42.13%	60.35%	59.41%	50.87%	43.54%	35.19%	32.71%	22.90%
Debt to EBITDA	-0.68	-0.58	-1.10	-1.11	-1.00	-0.83	-0.66	-0.64	-0.65	-0.71
Net Debt to EBITDA	0.85	0.58	0.66	1.54	1.26	0.91	0.51	0.43	0.46	0.46
Long-Term Debt to EBITDA	-0.63	-0.54	-1.05	-1.07	-0.96	-0.80	-0.64	-0.62	-0.62	-0.68
Debt to NOPAT	-0.95	-0.80	-1.48	-1.51	-1.36	-1.14	-0.91	-0.89	-0.89	-0.98
Net Debt to NOPAT	1.19	0.80	0.90	2.09	1.72	1.24	0.71	0.59	0.64	0.63
Long-Term Debt to NOPAT	-0.88	-0.75	-1.43	-1.45	-1.31	-1.10	-0.88	-0.85	-0.85	-0.94
Altman Z-Score	4.07	6.63	4.57	4.84	5.08	4.35	4.07	3.31	3.75	2.84
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.19	2.54	3.02	4.52	4.46	3.63	3.20	2.48	2.44	2.11
Quick Ratio	4.11	2.47	2.89	4.39	4.32	3.46	3.01	2.34	2.30	1.99
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-83	-73	-44	-29	-50	-49	-28	-6.37	37	4.83
Operating Cash Flow to CapEx	-34,481.82%	-15,228.18%	-8,198.59%	-41,615.79%	-14,433.42%	-433,742.86%	-54,558.16%	-57,903.85%	-20,701.11%	-87,340.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.11	0.24	0.61	0.46	0.48	0.59	0.54	0.50	0.58	0.67
Accounts Receivable Turnover	0.00	0.00	0.00	4.37	4.53	4.08	3.43	3.11	3.34	3.26
Inventory Turnover	0.00	0.00	0.00	1.67	3.47	2.68	2.11	2.31	2.49	2.16
Fixed Asset Turnover	54.50	99.49	248.49	266.29	279.65	345.15	331.38	399.30	409.26	539.43
Accounts Payable Turnover	0.08	0.09	0.22	0.23	0.26	0.24	0.21	0.20	0.21	0.19
Days Sales Outstanding (DSO)	0.00	0.00	0.00	83.58	80.63	89.37	106.31	117.55	109.20	112.06
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	218.24	105.16	136.22	173.06	158.03	146.70	169.15
Days Payable Outstanding (DPO)	4,814.76	3,956.17	1,690.30	1,607.53	1,395.57	1,550.29	1,699.86	1,849.36	1,778.48	1,924.37
Cash Conversion Cycle (CCC)	-4,814.76	-3,956.17	-1,690.30	-1,305.71	-1,209.78	-1,324.70	-1,420.49	-1,573.79	-1,522.58	-1,643.17
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	31	8.87	19	25	37	-11	-0.63	-23	-43	-66
Invested Capital Turnover	6.40	-7.77	-162.02	5.52	6.59	-290.03	27.46	404.00	-107.50	-10.00
Increase / (Decrease) in Invested Capital	53	31	40	-16	6.31	-20	-20	-48	-80	-56
Enterprise Value (EV)	1,672	3,249	2,591	2,877	3,066	3,564	3,631	3,697	4,178	3,977
Market Capitalization	1,798	3,349	2,684	3,131	3,298	3,766	3,776	3,823	4,314	4,100
Book Value per Share	$3.90	$2.52	$2.57	$6.40	$5.71	$4.04	$3.04	$2.17	$1.94	$1.18
Tangible Book Value per Share	$2.09	$0.91	$1.00	$4.83	$4.29	$2.66	$1.69	$0.86	$0.67	($0.04)
Total Capital	258	210	265	462	454	375	331	292	284	249
Total Debt	101	100	154	183	184	184	187	189	191	192
Total Long-Term Debt	94	94	148	177	177	178	180	182	183	184
Net Debt	-127	-101	-93	-254	-232	-202	-145	-126	-136	-123
Capital Expenditures (CapEx)	0.07	0.18	0.07	0.13	0.37	0.01	0.10	0.05	0.09	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-28	-46	-37	-26	-13	-14	-8.61	-32	-36	-52
Debt-free Net Working Capital (DFNWC)	199	155	210	411	404	372	323	283	291	263
Net Working Capital (NWC)	192	149	204	405	397	365	316	276	283	255
Net Nonoperating Expense (NNE)	15	19	6.76	22	19	30	21	25	21	24
Net Nonoperating Obligations (NNO)	-127	-101	-93	-254	-232	-202	-145	-126	-136	-123
Total Depreciation and Amortization (D&A)	2.13	2.04	2.25	2.60	2.37	2.19	2.45	2.63	2.73	2.78
Debt-free, Cash-free Net Working Capital to Revenue	-110.73%	-91.65%	-25.39%	-14.28%	-5.72%	-5.31%	-3.43%	-11.03%	-10.72%	-13.51%
Debt-free Net Working Capital to Revenue	775.74%	309.73%	145.07%	225.24%	180.71%	137.40%	128.61%	97.26%	86.00%	68.25%
Net Working Capital to Revenue	748.46%	297.94%	140.93%	221.77%	177.72%	135.04%	126.06%	94.84%	83.59%	66.10%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.07)	($1.44)	($0.26)	($1.54)	($1.32)	($2.15)	($1.44)	($1.67)	($1.34)	($1.54)
Adjusted Weighted Average Basic Shares Outstanding	41.70M	40.66M	43.52M	43.67M	47.12M	45.43M	47.39M	47.57M	48.14M	47.91M
Adjusted Diluted Earnings per Share	($1.07)	($1.44)	($0.26)	($1.54)	($1.32)	($2.15)	($1.44)	($1.67)	($1.34)	($1.54)
Adjusted Weighted Average Diluted Shares Outstanding	41.70M	40.66M	43.52M	43.67M	47.12M	45.43M	47.39M	47.57M	48.14M	47.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	43.43M	43.52M	43.57M	47.19M	47.32M	47.37M	47.50M	48.00M	48.46M	48.77M
Normalized Net Operating Profit after Tax (NOPAT)	-30	-42	-4.46	-46	-43	-69	-47	-55	-44	-51
Normalized NOPAT Margin	-176.23%	-172.10%	-4.72%	-97.52%	-75.24%	-96.17%	-62.79%	-62.68%	-41.84%	-42.80%
Pre Tax Income Margin	-266.08%	-251.29%	-9.13%	-145.15%	-108.80%	-138.37%	-91.14%	-91.03%	-61.67%	-63.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-3.73%	0.00%	-10.21%	-7.76%	-6.55%	0.00%	-0.74%	-0.16%	-0.28%

Frequently Asked Questions About Axsome Therapeutics' Financials

When does Axsome Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Axsome Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Axsome Therapeutics' net income changed over the last 9 years?

Axsome Therapeutics' net income appears to be on an upward trend, with a most recent value of -$287.22 million in 2024, rising from -$12.21 million in 2015. The previous period was -$239.24 million in 2023. View Axsome Therapeutics' forecast to see where analysts expect Axsome Therapeutics to go next.

What is Axsome Therapeutics's operating income?

Axsome Therapeutics's total operating income in 2024 was -$280.56 million, based on the following breakdown:

Total Gross Profit: $352.39 million
Total Operating Expenses: $632.95 million

How has Axsome Therapeutics revenue changed over the last 9 years?

Over the last 9 years, Axsome Therapeutics' total revenue changed from $0.00 in 2015 to $385.69 million in 2024, a change of 38,569,300,000.0%.

How much debt does Axsome Therapeutics have?

Axsome Therapeutics' total liabilities were at $511.48 million at the end of 2024, a 28.8% increase from 2023, and a 19,334.0% increase since 2015.

How much cash does Axsome Therapeutics have?

In the past 9 years, Axsome Therapeutics' cash and equivalents has ranged from $13.97 million in 2018 to $386.19 million in 2023, and is currently $315.35 million as of their latest financial filing in 2024.

How has Axsome Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Axsome Therapeutics' book value per share changed from 3.89 in 2015 to 1.18 in 2024, a change of -69.7%.

Related Companies

This page (NASDAQ:AXSM) was last updated on 5/6/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Axsome Therapeutics (AXSM) Financials

Frequently Asked Questions About Axsome Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Axsome Therapeutics (AXSM) Financials

Annual Income Statements for Axsome Therapeutics

Quarterly Income Statements for Axsome Therapeutics

Annual Cash Flow Statements for Axsome Therapeutics

Quarterly Cash Flow Statements for Axsome Therapeutics

Annual Balance Sheets for Axsome Therapeutics

Quarterly Balance Sheets for Axsome Therapeutics

Annual Metrics and Ratios for Axsome Therapeutics

Quarterly Metrics and Ratios for Axsome Therapeutics

Frequently Asked Questions About Axsome Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools